Invivyd, Inc.

IVVD

US00534A1025

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 05/12/2025 GMT			5-day change	1st Jan Change
2.230 ^USD	+0.45%		-4.29%	+403.27%

11-24	Invivyd Selects Antibody Candidate for Respiratory Syncytial Virus Prevention	MT
11-24	Invivyd, Inc. Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329	CI

Invivyd prices 44 million shares at $2.50 each

Published on 11/18/2025 at 03:42 am GMT

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Invivyd, Inc.

11-24	Invivyd Selects Antibody Candidate for Respiratory Syncytial Virus Prevention	MT
11-24	Invivyd, Inc. Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329	CI
11-18	Invivyd Prices $125 Million Securities Offering; Shares Down Pre-Bell	MT
11-18	Invivyd prices 44 million shares at $2.50 each	RE
11-17	Invivyd Launches Public Stock Offering	MT
11-14	Top Premarket Gainers	MT
11-06	Invivyd, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-24	Invivyd, Inc., Q3 2025 Earnings Call, Nov 06, 2025
11-06	Invivyd Q3 net loss beats estimates on higher PEMGARDA sales among healthcare providers	RE
10-31	Invivyd, Inc. - Special Call
10-20	Certain Warrants of Invivyd, Inc. are subject to a Lock-Up Agreement Ending on 20-OCT-2025.	CI
10-20	Certain Restricted stock units of Invivyd, Inc. are subject to a Lock-Up Agreement Ending on 20-OCT-2025.	CI
10-20	Certain Options of Invivyd, Inc. are subject to a Lock-Up Agreement Ending on 20-OCT-2025.	CI
10-20	Certain Common Stock of Invivyd, Inc. are subject to a Lock-Up Agreement Ending on 20-OCT-2025.	CI
10-06	Invivyd, Inc. Announces U.S. Food and Drug Administration Clearance of Investigational New Drug Application and Provide Feedback to Advance the Company's Revolation Clinical Program	CI
10-06	Cantor Fitzgerald Initiates Invivyd at Overweight With $10 Price Target	MT
10-06	Invivyd Gets FDA Clearance for VYD2311 Investigational New Drug Application; Shares Up Pre-Bell	MT
10-06	Invivyd Shares Climb After FDA Advances Its Covid-Preventing Drug	DJ
10-06	Invivyd gets FDA nod to start key trial of COVID-blocking antibody VYD2311	RE
10-02	Invivyd Files $350 Million Mixed Shelf Offering	MT
09-24	Invivyd appoints Paul B. Bolno, M.D. to its board of directors	RE
09-23	Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors	CI
09-17	Invivyd, Inc. Appoints Kristie Kuhl as Chief Communications Officer	CI
09-17	Invivyd announces appointment of Kristie Kuhl as Chief Communications Officer	RE
09-04	SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd's VYD2311 At Recover-TLC Workshop	CI

Invivyd, Inc. is a commercial-stage company, which is engaged in delivering antibody-based therapies. The Companyâs proprietary INVYMAB platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to keep pace with evolving viral threats. The Company delivers antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, such as SARS-CoV-2 (COVID-19). Its PEMGARDA is the Companyâs first mAb in a planned series of innovative mAb candidates designed to keep pace with SARS-CoV-2 viral evolution. Its VYD2311 is optimized for neutralization potency against recent SARS-CoV-2 lineages such as BA.2.86 and JN.1. The Company also has additional anti-SARS-CoV-2 mAb candidates in discovery and pre-clinical characterization.

Employees

100

Sector

Pharmaceuticals

Calendar

03-25 - Q4 2025 Earnings Release (Projected)

More about the company